Anixa Biosciences Inc
ANIXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | $210,000 | $210,000 | — | $512,000 | — |
| Operating income | −$11.7M | −$13.8M | −$11.0M | −$13.9M | −$13.1M | −$10.0M |
| Net income | −$10.9M | −$12.6M | −$9.8M | −$13.6M | −$13.0M | −$10.0M |
| Total assets | $16.1M | $21.6M | $25.5M | $30.4M | $36.3M | $9.5M |
| Total liabilities | $2.1M | $2.7M | $2.2M | $2.2M | $1.5M | $1.2M |
| Equity | $15.2M | $20.0M | $24.3M | $29.0M | $35.4M | $8.8M |
| EPS (diluted) | $-0.34 | $-0.39 | $-0.32 | $0.45 | $-0.45 | — |
| Shares out. | 32.2M | 31.7M | 30.9M | 30.1M | 26.1M | 20.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −72.1%
- Return on assets
- −68.0%
- Return on capital (ROCE)
- −82.9%
- Liabilities / assets
- 13.2%
- Debt / equity
- 0.14×
- Book value / share
- $0.47
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -42.76distress
- Accruals / assets
- −23.3%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Jan 31, 2011
- NT 10-Qmissed a reporting deadline ↗Jun 10, 2009
- NT 10-Kmissed a reporting deadline ↗Jan 15, 2009
- NT 10-Qmissed a reporting deadline ↗Sep 10, 2008
- NT 10-Qmissed a reporting deadline ↗Mar 12, 2008
- NT 10-Kmissed a reporting deadline ↗Jan 15, 2008
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Catelani MichaelActivist (13D)Jan 6, 2026
- Kumar AmitActivist (13D)Jun 6, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 983,354 | 8.7 | -5.1% |
| Apr 30, 2026 | 1.0M | 8.5 | -0.7% |
| Apr 15, 2026 | 1.0M | 9.7 | -9.3% |
| Mar 31, 2026 | 1.1M | 10.8 | -0.1% |
| Mar 13, 2026 | 1.2M | 11.5 | -0.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder vote · Regulation FD disclosureMar 11, 2026
- Regulation FD disclosureFeb 9, 2026
- Regulation FD disclosureDec 12, 2025
- Shareholder vote · Regulation FD disclosureMar 21, 2025
- Regulation FD disclosureNov 8, 2024
- Entered a material agreement · Regulation FD disclosureMay 8, 2024
- Shareholder vote · Regulation FD disclosureMar 22, 2024
- Regulation FD disclosureDec 7, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.